Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) announced two presentations for the AACR 2020 Virtual Annual Meeting, showcasing its AI platform RADR® in the development of LP-184, a drug candidate targeting specific tumors. The first abstract will detail LP-184's nanomolar potency and effectiveness against multi-drug resistant tumors. The second will explore a machine learning-derived genomic signature for predicting responses to LP-184. The company aims to leverage these findings for advancing their oncology drugs, enhancing treatment outcomes for patients.